Amyris (AMRS) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings or view top-rated stocks.

5 analysts have issued twelve-month target prices for Amyris' stock. Their AMRS share price forecasts range from $0.65 to $6.00. On average, they expect the company's stock price to reach $3.06 in the next twelve months. This suggests a possible upside of 6,014.3% from the stock's current price.
View analysts price targets for AMRS or view top-rated stocks among Wall Street analysts.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AMRS earnings forecast.

Amyris, Inc. (NASDAQ:AMRS) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $47.90 million during the quarter, compared to the consensus estimate of $64.21 million. The firm's revenue for the quarter was up 39.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) EPS.

ETFs with the largest weight of Amyris (NASDAQ:AMRS) stock in their portfolio include AXS Cannabis ETF (THCX).VegTech Plant-based Innovation & Climate ETF (EATV).

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.27%), DLD Asset Management LP (0.00%), Baird Financial Group Inc. (0.71%), Charles Schwab Investment Management Inc. (0.44%), Bank of New York Mellon Corp (0.34%) and Boothbay Fund Management LLC (0.00%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo and Nicole Kelsey.
View institutional ownership trends.

One share of AMRS stock can currently be purchased for approximately $0.05.

Amyris (NASDAQ:AMRS) has a market capitalization of $18.47 million and generates $269.85 million in revenue each year. The biotechnology company earns $-528,510,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

The company employs 1,598 workers across the globe.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.